<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECF8F3C9-3B3A-43F7-9D68-C558B80BF117"><gtr:id>ECF8F3C9-3B3A-43F7-9D68-C558B80BF117</gtr:id><gtr:name>Motor Neurone Disease Association (MND)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECF8F3C9-3B3A-43F7-9D68-C558B80BF117"><gtr:id>ECF8F3C9-3B3A-43F7-9D68-C558B80BF117</gtr:id><gtr:name>Motor Neurone Disease Association (MND)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/348FE8B2-125A-4F5E-AC31-CC9159532CE5"><gtr:id>348FE8B2-125A-4F5E-AC31-CC9159532CE5</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Wilmut</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/274F901D-01AB-4569-9304-5487B654A386"><gtr:id>274F901D-01AB-4569-9304-5487B654A386</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Briscoe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/16361F0C-3B70-4B91-BE7D-52A744E2BFD7"><gtr:id>16361F0C-3B70-4B91-BE7D-52A744E2BFD7</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>McWhir</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62211B96-56AF-4672-8BA7-754E3F0AC07B"><gtr:id>62211B96-56AF-4672-8BA7-754E3F0AC07B</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2C01491D-FC71-490B-98B1-71797B9BF11A"><gtr:id>2C01491D-FC71-490B-98B1-71797B9BF11A</gtr:id><gtr:firstName>Jack</gtr:firstName><gtr:surname>Price</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300329"><gtr:id>D1B01937-9880-4A33-800F-78B4E235502B</gtr:id><gtr:title>The application of embryonic stem cells to study motor neurone disease: exploring models mechanisms and therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300329</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-01-09</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>328748</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Motor Neurone Disease Association (MND)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Investigating the role of autophagy and the UPS in TDP-ALS</gtr:description><gtr:id>A56EAA12-2192-49BB-B11A-CB4664854DCC</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>56d46514219cf7.09918418-1</gtr:outcomeId><gtr:partnerContribution>Financial Support</gtr:partnerContribution><gtr:piContribution>ALS pathobiology</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Neuroscience Eli Lilly</gtr:department><gtr:description>Identification of compounds that enhance TDP43 clearance in ALS and FTD</gtr:description><gtr:id>5852A260-5591-4B68-B60E-5C0A28DCF707</gtr:id><gtr:impact>About to start</gtr:impact><gtr:outcomeId>56d463354455c9.23178454-1</gtr:outcomeId><gtr:partnerContribution>Expertise in drug discovery</gtr:partnerContribution><gtr:piContribution>Identify therapeutic targets for drug discovery</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medical Research Foundation</gtr:department><gtr:description>From ALS exomes to Functional assays: turning candidates into confirmed genes</gtr:description><gtr:id>77A25235-7960-43E9-91D6-BB25EF0698CB</gtr:id><gtr:impact>None yet as started 5 months ago</gtr:impact><gtr:outcomeId>56d463b5a62d80.69479121-1</gtr:outcomeId><gtr:partnerContribution>financial support</gtr:partnerContribution><gtr:piContribution>Scientific expertise on ALS pathogenesis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Motor Neurone Disease Association (MND)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Generation and characterisation of induced pluripotent stem cells from ALS lymphoblasts to model disease pathogenesis and advance drug discovery</gtr:description><gtr:id>350E2491-2AC6-4E16-A4BE-D143074B81CC</gtr:id><gtr:impact>Nil yet as just started</gtr:impact><gtr:outcomeId>56d4666230d658.20062502-1</gtr:outcomeId><gtr:partnerContribution>Financial and access to lymphoblast cell lines</gtr:partnerContribution><gtr:piContribution>Research excellence</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>The Use of Mass Spectrometry for Multi-site Phosphorylation Assays for Tau Protein</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>B9A8F8C1-661A-460C-90AD-718B0C80C8DB</gtr:id><gtr:impact>Poster presentation at International Conference on Alzheimer's Disease, Chicago

None</gtr:impact><gtr:outcomeId>154D6F59B6C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>4AC27991-1726-449F-9A33-27482E69EB46</gtr:id><gtr:impact>Our Open Day is for patients and carers with approximately 150 attendees. We organise 8 laboratory demonstrations presented by PhD students and postdoctoral researchers around which small groups (6-8 persons) circulate. We also have a group of about 12 sixth form students who perform a laboratory experiment. At the end of the day the sixth formers present their results to the who audience and this is followed by an &amp;quot;Any Questions&amp;quot; session with clinical and non-clinical experts answering questions from the visitors.

The Open Day has now been run on three occasions and each time has received universal acclaim from visitors. The report is also made available on our web site.</gtr:impact><gtr:outcomeId>4C98074F446</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Many media interviews TV, Radio, Newspapers, Radio</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>CE8E0C27-5AFB-48BD-9B37-568788DCF4DF</gtr:id><gtr:impact>Many media interviews TV, Radio, Newspapers, Radio

Legislation modified</gtr:impact><gtr:outcomeId>9AE0CB30EDC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Peterborough</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>8C7365E8-5774-46B2-BEA5-74058A97367C</gtr:id><gtr:impact>Lectured to school students and informal chat

Enthusiastic discussion</gtr:impact><gtr:outcomeId>BB2D8E9C3C7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A51BC6CB-4B89-48B2-B520-892A34BD4863</gtr:id><gtr:impact>Public lecture on the genetics and biology of motor neuron disease</gtr:impact><gtr:outcomeId>58c93f4e8924f4.27061276</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture on motor neuron disease research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3CBEF8F3-02F7-4F63-A927-7EC072AC2877</gtr:id><gtr:impact>I spoke at a dinner hosted by the MND Association for major donors at the Royal Institution</gtr:impact><gtr:outcomeId>58c93ff0bc3547.27040784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sleep and circadian rhythm disorder in Parkinson's Disease:  association with hallucinations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>4EE0A1DC-07EA-415C-9B68-380222469ABA</gtr:id><gtr:impact>A world conference on sleep.

Received a citation award.</gtr:impact><gtr:outcomeId>0041A34B2A3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient and Carers meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>97056230-E732-4595-9E03-882B236B8118</gtr:id><gtr:impact>40-60 Patients and Carers lasting 1.5 hours of talk and discussion

Members of the audience are fundraising for a studentship for my laboratory</gtr:impact><gtr:outcomeId>sfMRufTmbZ7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient and Carers meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>5597022D-3ACF-430A-AC00-3A751FB4AF2B</gtr:id><gtr:impact>Each meeting has 40-60 attendees and lasts 1.5 hours with talk and questions

Patients have come to our laboratory open day and are actively fundraising to create a studentship</gtr:impact><gtr:outcomeId>tGyn6nSUUeL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Multi-site Phosphorylation Assays for Tau Protein and their relevance to Alzheimer's disease and other neurological disorders</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>5E1FBE68-4DF7-4573-8D6E-99217D39EE4B</gtr:id><gtr:impact>Poster presentation at American Society of Mass Spectrometry conference

None</gtr:impact><gtr:outcomeId>0E3C0190618</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented to Members of Parliament</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>293D5526-92DE-4246-B01B-44434C89868A</gtr:id><gtr:impact>Presented to parliamentary parties

Legeislation changed</gtr:impact><gtr:outcomeId>4945B48396A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Darwin Trust of Edinburgh</gtr:department><gtr:description>Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Society for the History of Science (BSHS)</gtr:fundingOrg><gtr:id>08D5FC82-D676-41EB-BD01-6D2F10E22F84</gtr:id><gtr:outcomeId>58c93dbea62219.99794471</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87502</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>75BC06F9-324A-4657-A9B0-7E1459646CED</gtr:id><gtr:outcomeId>pVEA2SfsXd90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Biomedical Sciences Institute PhD Studentship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>D2047B5C-7074-4CA4-8E25-04F912B12B1D</gtr:id><gtr:outcomeId>58c93d5ceb05d9.47554176</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Case Studentship</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1ADC2819-6AB5-4088-AABF-A29ABD110441</gtr:id><gtr:outcomeId>58c93c427e3264.75924272</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sumission to Parliamentary Science and Technology Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>3D42F339-9668-46F8-946C-39D06C96DF19</gtr:id><gtr:impact>Permitted the use of hybrid embryos in research in UK</gtr:impact><gtr:outcomeId>E70B2D9560D</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B38440AF-D146-4498-BBAD-C1DB06EF0C42</gtr:id><gtr:title>Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ecfd0497d0375c0a88359b331f4d279"><gtr:id>6ecfd0497d0375c0a88359b331f4d279</gtr:id><gtr:otherNames>Alami NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>544bcf031799a2.08217536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E79DCBE8-DFF8-459A-84FA-A69A57D53061</gtr:id><gtr:title>Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/648ce689029eb74519bb3610828d1173"><gtr:id>648ce689029eb74519bb3610828d1173</gtr:id><gtr:otherNames>van Eijk RPA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5aa699e5ebbea6.81534669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC65FB7B-0F64-4C3F-8B08-BDEA016E3433</gtr:id><gtr:title>ATXN2 trinucleotide repeat length correlates with risk of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdc6e29ff1fbfb82d08db9aa811d9c11"><gtr:id>fdc6e29ff1fbfb82d08db9aa811d9c11</gtr:id><gtr:otherNames>Sproviero W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5aa699e29b59d1.36739737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D85426E-67F0-4494-B6E7-7F36FC849E7E</gtr:id><gtr:title>Neuromuscular disease: new insights and avenues for therapy.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>544bcf019cb4a7.27593700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88591F85-122C-4BC0-A1B6-CF3201BB1077</gtr:id><gtr:title>Maturation and electrophysiological properties of human pluripotent stem cell-derived oligodendrocytes.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a870ddbc6f40ddea0dc8f5449c90bb5d"><gtr:id>a870ddbc6f40ddea0dc8f5449c90bb5d</gtr:id><gtr:otherNames>Livesey MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>56d4623a8e71d3.84842728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F6D93E8-CB22-4074-9D87-26BA1B6296DA</gtr:id><gtr:title>Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5aa699e3687533.67844697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57FE23F1-DD51-4141-959B-DD1BF1804C64</gtr:id><gtr:title>Comment on &amp;quot;Drug screening for ALS using patient-specific induced pluripotent stem cells&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>544bcf01f119e7.52699369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>368D2947-90F5-4F55-BCD9-E80672FD7676</gtr:id><gtr:title>Unpicking neurodegeneration in a dish with human pluripotent stem cells: one cell type at a time.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>544bcf0229e0f0.81404388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85E39A1F-04DD-4F6A-9DA2-111C1B938C0C</gtr:id><gtr:title>Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0355658aee7a567caa922e6adbda88b6"><gtr:id>0355658aee7a567caa922e6adbda88b6</gtr:id><gtr:otherNames>Zhang Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_12421_ne_0076055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>368426F3-76A5-4260-8191-E7F619888ED6</gtr:id><gtr:title>Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c831250c6d5af43302dbd12e99b4fb6"><gtr:id>1c831250c6d5af43302dbd12e99b4fb6</gtr:id><gtr:otherNames>Lee YB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_540e16ae16a8e0adb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64464823-13B1-49E3-9BA5-4AB36DE8AE2C</gtr:id><gtr:title>The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aa73e328eb61ebd7307a45f0b5976b5"><gtr:id>9aa73e328eb61ebd7307a45f0b5976b5</gtr:id><gtr:otherNames>Martin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5aa699e4e53521.11586011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>183B6ED5-7B68-41B7-B419-70E7F14A8745</gtr:id><gtr:title>RNA Misprocessing in-Linked Neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9adb0cf9c748d2062adf63457cc15ba4"><gtr:id>9adb0cf9c748d2062adf63457cc15ba4</gtr:id><gtr:otherNames>Barker HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>5aa699e5738790.24080771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B2DCA1C-E844-492D-89F7-4442C3469DD2</gtr:id><gtr:title>Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9da89c318f56fc7256d9d74b60d23229"><gtr:id>9da89c318f56fc7256d9d74b60d23229</gtr:id><gtr:otherNames>Sims R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5aa699e46a4a55.51168519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3447DF9C-F275-40D5-BD06-1B6734655B13</gtr:id><gtr:title>Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107e692c5cbfdd08a4bdfa319afca3cb"><gtr:id>107e692c5cbfdd08a4bdfa319afca3cb</gtr:id><gtr:otherNames>Vance C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>D85B3233FBD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>304AEB24-2672-41E1-83B3-74B5729F7CFB</gtr:id><gtr:title>A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2841aab396cd2b4f18a94e7a29ae23"><gtr:id>aa2841aab396cd2b4f18a94e7a29ae23</gtr:id><gtr:otherNames>Morgan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5aa699e3d49b28.83252519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C59F1D95-5B9A-41F1-84BA-E7D710C129AD</gtr:id><gtr:title>Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_12421_21_22451909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63A7BFA9-0945-4C1C-A390-A5E673C05EEE</gtr:id><gtr:title>Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3dac9ccb09aac2d119921cddc240716"><gtr:id>d3dac9ccb09aac2d119921cddc240716</gtr:id><gtr:otherNames>Serio A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_12421_1300398110</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300329</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>